Volker Berl

Founder, Managing Partner & CEO

2009 - Current

www.newageventures.net Globally active generalist Venture Studio with a rich portfolio of earlier stage and actively managed investments across healthcare, medical devices, digital health, cleantech, consumer tech, deep tech, applied artificial intelligence, and more.

Member of the Board of Directors, Chair Governance Committee, Member Audit & Compensation Committees

2021

www.standardlithium.com Standard Lithium is a leading near-commercial lithium development company focused on the sustainable development of a portfolio of lithium-brine bearing properties in the United States. The Company prioritizes brine projects characterized by high-grade resources, robust infrastructure, skilled labor, and streamlined permitting. The Company aims to achieve sustainable, commercial-scale lithium production via the application of a scalable and fully-integrated Direct Lithium Extraction (“DLE”) and purification process. The Company’s signature projects, the Phase 1A Project and the South West Arkansas Project, are located on the Smackover Formation in southern Arkansas, a region with a longstanding and established brine processing industry. The Company has also identified a number of highly prospective lithium brine project areas in the Smackover Formation in East Texas and began an extensive brine leasing program in the key project areas. In addition, the Company has an interest in certain mineral leases located in the Mojave Desert in San Bernardino County, California. Standard Lithium trades on both the TSX Venture Exchange and the NYSE American under the symbol “SLI”; and on the Frankfurt Stock Exchange under the symbol “S5L”. Please visit the Company’s website at www.standardlithium.com.

Strategic Advisor

2020 - 2021

Member of the Board of Directors

2022

www.femselect.com Developer of medical devices designed to treat pelvic organ prolapse. The company's devices offer a minimally-invasive surgical system for suturing ligaments of the pelvic floor without overnight hospital stays and scars, enabling physicians to conduct surgery without dissection or mesh.

Member of the Board of Directors

2017

www.venock.com Developer of a vascular closure device designed for very large bore access sites in veins and arteries resulting from interventional transcatheter therapies. The company's device is handheld, fully percutaneous, and allows cardiologists to attain full vascular closure in less time and to stop venous bleeding, followed by compression bandage and immobilization, enabling healthcare professionals to save time and cost while improving patient turnover and cath lab efficiency.

Member of the Board of Directors

2021

www.artract-medical.com Developer of hemodynamic assist device intended for the treatment of the heart. The company offers a passive hemodynamic assist device that is implanted percutaneously for the treatment of heart failure with preserved ejection fraction which reduces left atrial blood pressure, eases shortness of breath, increases heart chamber filling, and requires no energy source or motor, enabling patients to improve their life with the help of medical advancement.

Executive Director

2020

Financial Advisor

2017 - 2020

Developer of an artificial intelligence technology designed to deliver high-performance machine emotional awareness. The company's patented emotion synthesis for generative artificial intelligence models technology goes the next step by using emotion synthesis and AI to shape the machine's cognitive appraisal and response, thereby, enabling an AI, robotic toy, or IoT device to develop a unique personality based on its user interactionsinteraction, emotion speech synthesis, emotion speech recognition, emotional awareness, autonomy, emotion reasoning, machine emotional intimacy, AI’s personalities, machine learning, and affective computing.

Advisor

2017

Developer of a health assessment and management application designed to assist individuals in making decisions about cognitive health concerns. The company's application connects patients and care teams in both the concussion and dementia markets and also offers a screening tool and interactive tests that users can access to assess brain health on any mobile device or browser and receive results on the spot, enabling clinicians to track brain health for significant changes and share results with clinicians.

Member of the Board of Directors

2007 - 2024

www.gaussin.com GAUSSIN is an engineering company that designs, assembles and markets innovative products and services in the field of transport and logistics. Its know-how covers the transport of goods and people, autonomous technologies for driverless use such as Automotive Guided Vehicles, and the integration of all types of batteries, particularly electric and hydrogen batteries. With more than 50,000 vehicles worldwide, GAUSSIN enjoys a strong reputation in four rapidly expanding markets: port and airport terminals, logistics and people mobility. The group has signed agreements with global companies: Qatar Airways Cargo, Maersk APMT, UPS and Amazon. GAUSSIN has expanded its business model by signing licensing agreements to accelerate the distribution of its technology throughout the world. Gaussin has been listed on Euronext Growth in Paris since 2010.

Member of the Board of Directors, Audit Committee Chair

2021 - 2023

FTAC Zeus Acquisition Corp was a blank check company (IPO date: November 19th 2021; IPO Proceeds: 402.5m USD), seeking to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses or assets, with a focus to identifying technology and financial services technology, or fintech, companies that power transformation and innovation, globally or domestically.

Member of the Board of Directors, Member of the Audit Committee

2015 - 2022

OrthogenRx, Inc. was acquired by Avanos Medical, Inc. (NYSE:AVNS) on December 13, 2021. www.orthogenrx.com / now: www.avanos.com OrthogenRx, Inc. was a medical device company focused on the development and commercialization of treatments for knee pain caused by osteoarthritis (OA). OA is the most common cause of knee pain, causing sufferers significant pain and disability. OrthogenRx's knee joint pain injection products are safe, non-surgical alternatives developed to lubricate the joint and relieve mild to moderate knee pain for patients